The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) project aimed to determine the clinical utility of ß-amyloid PET imaging for the understanding, diagnosis and management of Alzheimer’s disease. Moreover, in combination with the European Prevention of Alzheimer’s disease (EPAD) study and other non-EPAD cohorts, the project aimed at unraveling the natural history of the disease in the preclinical or presymptomatic stage to assess the predictive value of ß-amyloid PET and ensure correct enrollment of patients into targeted treatment trials.